HPV and beyond—looking out for biomarkers for distinguishing the good prognosis from the bad prognosis group in locally advanced and clinically high risk HNSCC

摘要: In their recent editorial Kimple and Harari (1) reviewed the current knowledge of importance HPV status head neck squamous cell carcinoma (HNSCC) for outcome radiotherapy. The summarized, among others, a retrospective multicenter study by German Cancer Consortium Radiation Oncology Group (DKTK-ROG) which demonstrated significant prognostic value in patients with locally advanced HNSCC on postoperative radiochemotherapy (PORT-C) (2). overall aim DKTK-ROG program is to identify validate biomarkers including biological clinical parameters as well imaging data patient stratification terms individualization radiotherapy multimodal treatment. design includes explorative analyses who received PORT-C or primary (RCT) biomarker identification. most promising will then be validated prospective validation cohort, currently recruiting at all eight partner sites. Based these results, interventional studies are under preparation. Biomarker being performed DKTK sites addressing different topics such status, hypoxia, cancer stem cells, tumor infiltrating lymphocytes, volume, targeted next generation sequencing, transcriptomics methylome analyses.